LEADER 02030nam  2200589Ia 450 
001 9910780397503321
005 20230617025804.0
010   $a0-309-16677-2
010   $a1-280-17942-2
010   $a9786610179428
010   $a0-309-52720-1
035   $a(CKB)111087027008986
035   $a(OCoLC)54770887
035   $a(CaPaEBR)ebrary10051648
035   $a(SSID)ssj0000257443
035   $a(PQKBManifestationID)11216533
035   $a(PQKBTitleCode)TC0000257443
035   $a(PQKBWorkID)10228879
035   $a(PQKB)11356227
035   $a(MiAaPQ)EBC3564030
035   $a(Au-PeEL)EBL3564030
035   $a(CaPaEBR)ebr10051648
035   $a(EXLCZ)99111087027008986
100   $a20031202d2004      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aTestosterone and aging$b[electronic resource] $eclinical research directions /$fCommittee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy, Board on Health Sciences Policy ; Catharyn T. Liverman and Dan G. Blazer, editors
210   $aWashington, DC $cNational Academies Press$dc2004
215   $a1 online resource (237 p.) 
300   $aBibliographic Level Mode of Issuance: Monograph
311   $a0-309-09063-6 
320   $aIncludes bibliographical references.
606   $aLongevity
606   $aAging$xPrevention
606   $aTestosterone$xPhysiological effect
615  0$aLongevity.
615  0$aAging$xPrevention.
615  0$aTestosterone$xPhysiological effect.
676   $a612.6/8
701   $aLiverman$b Catharyn T$01086332
701   $aBlazer$b Dan G$g(Dan German),$f1944-$01492862
712 02$aNational Research Council (U.S.).$bCommittee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910780397503321
996   $aTestosterone and aging$93799860
997   $aUNINA